EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudie

Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study

Koichi Ogawa iD, Hitoshi Ishikawa, Takeshi Toyozumi, Kazuhiro Noma, Koji Kono, Hidehiro Hojo, Hiroyasu Tamamura, Yusuke Azami, Toshiki Ishida, Yoshihiro Nabeya, Hiromitsu Iwata, Masayuki Araya und 4 weitere

Esophagus · 2024

DOI: 10.1007/s10388-024-01068-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Esophagus, 2024. Verfasst von Koichi Ogawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 3…. Hauptthemen laut MEDLINE: Esophagectomy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Proton-based, definitive chemoradiotherapy (P-CRT) for esophageal squamous cell carcinoma (ESCC) previously showed comparable survival outcomes with the surgery-based therapy, i.e., neoadjuvant chemotherapy followed by esophagectomy (NAC-S), in a single-institutional study. This study aimed to validate this message in a Japanese multicenter study. METHODS: Eleven Japanese esophageal cancer specialty hospitals have participated. A total of 518 cases with clinical Stage I-IVA ESCC between 2010 and 2019, including 168 P-CRT and 350 NAC-S patients, were enrolled and long-term outcomes were evaluated. Propensity-score weighting analyses with overlap weighting for confounding adjustment were used. RESULTS: The 3-year overall survival (OS) of the P-CRT group was equivalent to the NAC-S group (74.8% vs. 72.7%, hazard ratio [HR]: 0.87, 95% confidence interval [CI]: 0.61-1.25). Although, the 3-year P-CRT group progression-free survival (PFS) was inferior to the NAC-S group (51.4% vs. 59.6%, HR 1.39, 95% CI 1.04-1.85), the progression P-CRT group cases showed better survival than the NAC-S group (HR 0.58, 95% CI 0.38-0.88), largely because of salvage surgery or endoscopic submucosal dissection for local progression. The survival advantage of P-CRT over NAC-S was more pronounced in the cT1-2 (HR 0.61, 95% CI 0.29-1.26) and cStage I-II (HR 0.50, 95% CI 0.24-1.07) subgroups, although this trend was not evident in other populations, such as cT3-4 and cStage III-IVA. CONCLUSIONS: Proton-based CRT for ESCC showed equivalent OS to surgery-based therapy. Especially for patients with cT1-2 and cStage I-II disease, proton-based CRT has the potential to serve as a first-line treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsophagectomyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsChemoradiotherapyProton TherapyHumansMaleFemaleMiddle AgedJapanRetrospective StudiesAgedNeoadjuvant TherapyNeoplasm StagingTreatment OutcomePropensity ScoreEast Asian People

Stichwörter der Autor:innen

Esophageal carcinomaEsophagectomyNeoadjuvant chemotherapyProton beam therapySalvage therapy

Autor:innen und Institutionen

  • Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. k-ogawa@md.tsukuba.ac.jp.
  • Department of Radiation Oncology, National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba, Japan.
  • Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
  • Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan.
  • Department of Radiation Oncology, National Cancer Hospital East, Chiba, Japan.

ORCID-Profile: Koichi Ogawa

Zitieren

APA

Ogawa, K., Ishikawa, H., Toyozumi, T., Noma, K., Kono, K., Hojo, H., Tamamura, H., Azami, Y., Ishida, T., Nabeya, Y., Iwata, H., Araya, M., Tokumaru, S., Maruo, K., Oda, T., & Matsubara, H. (2024). Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study. Esophagus. https://doi.org/10.1007/s10388-024-01068-6

Vancouver

Ogawa K, Ishikawa H, Toyozumi T, Noma K, Kono K, Hojo H, et al. Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study. Esophagus. 2024. doi:10.1007/s10388-024-01068-6

BibTeX
@article{Ogawa2024,
  author = {Ogawa, Koichi and Ishikawa, Hitoshi and Toyozumi, Takeshi and Noma, Kazuhiro and Kono, Koji and Hojo, Hidehiro and Tamamura, Hiroyasu and Azami, Yusuke and Ishida, Toshiki and Nabeya, Yoshihiro and Iwata, Hiromitsu and Araya, Masayuki and Tokumaru, Sunao and Maruo, Kazushi and Oda, Tatsuya and Matsubara, Hisahiro},
  title = {Comparison of proton-based definitive chemoradiotherapy and surgery-based therapy for esophageal squamous cell carcinoma: a multi-center retrospective Japanese cohort study},
  journal = {Esophagus},
  year = {2024},
  doi = {10.1007/s10388-024-01068-6}
}
Kostenlos starten →